Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?
This article was originally published in The Pink Sheet Daily
Executive Summary
With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.
You may also be interested in...
Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.
Ivermectin Settlement Brings Relief And Worry For US FDA Communications
The FDA’s decision to end litigation challenging an agency communication that tried to tackle COVID-19 misinformation leaves an appeals court opinion in place that could haunt it later. But continuing to fight the case could have left the agency in a far worse position.